Zimmer Biomet Holdings (ZBH) Reports In-Line Q4 EPS; Guides Q1 Modestly Below the Street

Go back to Zimmer Biomet Holdings (ZBH) Reports In-Line Q4 EPS; Guides Q1 Modestly Below the Street

Zimmer Biomet (ZBH) PT Raised to $138 at Baird on 4Q Report; 'Revenues Shows Signs of Stabilization'

January 31, 2018 8:18 AM EST

Baird raised its price target on Zimmer Biomet (NYSE: ZBH) to $138.00 (from $130.00) while maintaining a Outperform rating, following the company's fourth quarter earnings report.

Analyst Jeff Johnson notes a positive outlook on the shares, as ZBH reported fourth revenues above consensus... More

Zimmer Biomet (ZBH) PT Raised to $146 at Leerink Partners

January 31, 2018 7:50 AM EST

Leerink Partners raised its price target on Zimmer Biomet (NYSE: ZBH) to $146.00 (from $142.00) while maintaining a Outperform rating.

Analyst Richard Newitter commented, "Our OP rating is predicated on the view that for longer-term oriented investors we believe ZBH is a turnaround... More

Zimmer Biomet (ZBH) PT Raised to $155 at Needham & Company

January 30, 2018 1:11 PM EST

Needham & Company raised its price target on Zimmer Biomet (NYSE: ZBH) to $155.00 (from $144.00) while maintaining a Strong Buy rating following in-line Q4 results.

Analyst Mike Matson commented, "ZBH's 4Q17 revenue beat and EPS met consensus and 1Q18 guidance was below consensus. Margins... More